Deals channel feed

As­traZeneca en­lists UK Treg biotech for type 1 di­a­betes, in­flam­ma­to­ry bow­el dis­ease deal fea­tur­ing $85M up­front

Last year
Cell/Gene Tx

Q2 deal ac­tiv­i­ty points to po­ten­tial 'bumper year' for phar­ma — re­port

Last year
Pharma

Sam­sung Bi­o­log­ics se­cures $400M+ man­u­fac­tur­ing deal with Pfiz­er

Last year
Manufacturing

Af­ter gene ther­a­py deaths, Astel­las to re­vis­it fa­tal neu­ro­mus­cu­lar con­di­tion in part­ner­ship with biotech start­up

Last year
R&D
Cell/Gene Tx

Deer­field taps NYU Lan­gone Health as lat­est aca­d­e­m­ic part­ner, ink­ing $130M trans­la­tion­al re­search pact

2 years ago
Discovery

Bay­er gets its hands on Acuitas' LNP as it lines up first shots at gene edit­ing

2 years ago
Cell/Gene Tx

No­vo Hold­ings, Gur­net Point Cap­i­tal en­gi­neer $462M take-pri­vate deal for an­tibi­otics play­er Paratek

3 years ago

Idor­sia notes po­ten­tial $440.8M Asia li­cens­ing deal to ex­tend cash run­way amid slow Qu­viviq sales

3 years ago

Am­gen con­tin­ues to tar­get mid-De­cem­ber dead­line for Hori­zon deal close

3 years ago
Pharma

No­vo Nordisk un­veils $165M buy­out bid for a drug de­liv­ery part­ner on smart in­sulin pens

3 years ago

Take­da ax­es gene ther­a­py deal with Po­sei­da Ther­a­peu­tics amid broad­er re­think

3 years ago
Cell/Gene Tx

Ger­man ra­dio­phar­ma biotech ac­quires British start­up in tiny deal

3 years ago

Roger Perl­mut­ter builds Eikon's pipeline with deal-mak­ing flur­ry, rais­ing $106M more

3 years ago
Financing

Lon­za shells out $107M cash to snap up Synaf­fix and its ADC plat­form

3 years ago
Manufacturing

Yuhan Cor­po­ra­tion to pay $325M to in-li­cense pre­clin­i­cal HER2 can­di­date

3 years ago
Pharma

MEI Phar­ma re­ceives un­so­licit­ed of­fer as it pro­ceeds with In­fin­i­ty merg­er

3 years ago

C4 Ther­a­peu­tics gets $35M from Bet­ta Phar­ma­ceu­ti­cals to de­vel­op and mar­ket NSCLC drug in Chi­na

3 years ago
R&D
China

XtalPi inks $250M pact with Lil­ly af­ter Pfiz­er suc­cess

3 years ago
China
AI

Atea's board re­jects un­so­licit­ed cash of­fer from Tang Cap­i­tal's Con­cen­tra

3 years ago
People

Mer­ck­'s $10.8B Prometheus buy­out can pro­ceed af­ter an­titrust re­view

3 years ago
Pharma

UCB en­ters gene ther­a­py space, ink­ing li­cense agree­ment for epilep­sy and neu­rode­gen­er­a­tion re­search

3 years ago
Cell/Gene Tx

Small SPAC to tiny sale: Apex­i­gen sprints to Pyx­is On­col­o­gy in $16M ex­it

3 years ago

Atea con­firms un­so­licit­ed cash pro­pos­al from Tang Cap­i­tal’s Con­cen­tra, the shell buy­ing Jounce Ther­a­peu­tics

3 years ago

Co­hBar, Mor­pho­gen­e­sis link up in re­verse merg­er of two can­cer biotechs

3 years ago
R&D
First page Previous page 34353637383940 Next page Last page
A service from the Financial Times